Research
Novaerus devices have been shown to safely and effectively reduce airborne viruses, bacteria, mold spores, VOCs, and particulate matter in dozens of independent laboratory tests. In case studies and clinical trials, our devices have been demonstrated to reduce infections and improve wellbeing in real-world settings.
Utilizing NanoStrike Technology, Novaerus devices have been shown to safely and effectively reduce viruses, bacteria, mold spores, VOCs, and particulate matter in dozens of independent laboratory tests.
In case studies and clinical trials, our products have been demonstrated to reduce infections and improve wellbeing in real-world settings.
Viruses
Name Reduc. Model SARS-CoV-2 99.75% NV400 SARS-CoV-2 99.997% NV1050 MS2 Bacteriophage, SARS-CoV-2, RSV, Influenza A, Norovirus surrogate 99.99% NV1050 Human parainfluenza type 3 (HPIV3), Measles surrogate 99.87% NV1050 Influenza A 99.9% NV1050 Phi X 174, Hepatitis B23, Hepatitis C23, HIV2 surrogate 98.8% NV1050 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.9995% NV400 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.99% NV800 MS2 Bacteriophage, Norovirus surrogate 99.99% NV800 MS2 Bacteriophage, Influenza A surrogate 99.99% NV800 MS2 Bacteriophage, SARS-CoV-2 surrogate 99.991% NV200 
Bacteria
Name Reduc. Model Bacillus globigii endospores, Anthrax surrogate 99.99% NV1050 Clostridicum difficile spores 99.9% NV1050 Micrococcus luteus 99.2% NV1050 Mycobacterium smegmatis, Tuberculosis surrogate 97% NV1050 Staphylococcus epidermidis, MRSA surrogate 99.94% NV1050 Staphylococcus epidermidis 99.9% NV1050 Bacillus globigii endospores, Anthrax surrogate 99.9969% NV400 Micrococcus luteus 97.7% NV400 Staphylococcus epidermidis, MRSA surrogate 99.99% NV400 MRSA 99.99% NV800 Bacillus subtilis 86.63% NV800 Acinetobacter species 0 growth NV200 Enterobacter cloacae 99.99% NV 1050 Salmonella enterica 99.99% NV 1050 Listeria innocua 99.99% NV 1050 
Mould Spores
Name Reduc. Model Aspergillus niger 99.99% NV1050 Aspergillus niger 99.10% NV800 
VOCs
Name Reduc. Model Nitrogen Dioxide 99.49% NV1050 Formaldehyde 99.68% NV1050 Toluene 99% NV1050 - SARS-CoV-2 Reduction
The Defend 1050 achieved a 4.53 log10 reduction of live SARS-CoV-2 virus, which equates to a 99.997% percentage reduction, in 30 minutes. The live SARS-CoV-2 virus was not detectable after 30 minutes.
SARS-CoV-2 ReductionThe Novaerus Defend 400 achieved an average live SARS-CoV-2 virus reduction of 8.76 x 103 TCID50/mL, which equates to a 99.86% percentage reduction, after 45 minutes. A net reduction of 99.75% was achieved with the device operating for a total of the 45 minutes time point.
SARS-CoV-2 ReductionNovaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories.
SARS-CoV-2 ReductionNovaerus Defend 400 was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.9995% in 45 minutes at Aerosol Research and Engineering Laboratories in Kansas.
SARS-CoV-2 ReductionThe Protect 200 (NV200/330) was shown to reduce MS2 bacteriophage, a surrogate for SARS-CoV-2, by 99.991% in 180 minutes at Aerosol Research and Engineering Laboratories in Kansas.
Air ExchangeNovaerus NV950 (Protect 800/900) cleaned 100% of the air in a room of 22.65m3 (800 ft3) in 21-24 minutes, dependent on fan speed at the Cork Institute of Technology in Cork, Ireland.
Ozone Test - Protect 200Novaerus Protect 200 (NV200/330) passed standard UL testing with a maximum ozone concentration of 0.037 ppm at UL Environment in Georgia.
Ozone Test - Protect 800Novaerus Protect 800 passed standard UL testing with a maximum ozone concentration of 0.017 ppm with fan on high speed setting and 0.020 ppm with fan on low speed setting at Intertek in New York.
Ozone Test - Protect 900Novaerus Protect 900 passed standard UL testing with a maximum ozone concentration of 0.026 ppm with fan on high speed setting and 0.006 ppm with fan on low speed setting at UL Environment in Georgia, USA.
Airborne Allergen ReductionNovaerus Protect 800/900 was shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen at Indoor Biotechnologies Ltd. in Cardiff, UK.
Aspergillus niger Spore ReductionNovaerus Defend 1050 was shown to reduce aerosolized Aspergillus niger spores at the Aerosol Research and Engineering Laboratories.
Bacillus Globigii Endospores ReductionThe Defend 1050 showed a 4-log (99.99%) reduction in Bacillus Globigii endospores within 15 minutes, which was maintained over the prolonged operation (24 hours).
Bacillus Globigii Endospores ReductionThe Defend 400 achieved a net LOG reduction of Bacillus Globigii endospores after 45 minutes of 4.55 which is equivalent to a net percent reduction of 99.9969%.
Bioaerosols ReductionNovaerus Protect 800/900 was shown to reduce aerolized biologicals: Staphylococcus epidermidis (99.87% reduction), MS2 bacteriophage (99.99% reduction), Aspergillus niger fungus (99.1% reduction), and Bacillus subtilis endospores (86.63% reduction) at the Aerosol Research and Engineering Laboratories.
Clostridium difficile Spore ReductionNovaerus Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and >99.9% after 40 minutes at the Airmid Health Group Ltd. in Ireland.
Influenza A ReductionNovaerus Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation at the Airmid Health Group Ltd. in Ireland.
Influenza H1N1 ReductionThe Protect 200 (NV200/330) was effective at removing 51.8% of the Influenza H1N1 virus from the air after 1 passage (or 44 seconds) through the device.
Formaldehyde ReductionNovaerus Defend 1050 had an average net LOG reduction of 2.52 LOG across four tests and formaldehyde levels reached 0.00 ppm in an average of 1.1 minutes at the Aerosol Research and Engineering Laboratories.
Formaldehyde ReductionNovaerus Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment using Avomeen Analytical Services in Michigan.
Measles Virus ReductionDefend 1050 was able to reduce the concentration of human parainfluenza type 3 (HPIV3) (renamed human respirovirus 3), a surrogate for Measles virus, by 99.87% after 25 minutes at Airmid Healthgroup in Ireland.
Methicillin-resistant Staphylococcus aureus (MRSA) ReductionNovaerus Protect 800/900 reduced 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) bacteria over the course of four hours at Microbac Laboratories, Inc. in North Carolina.
Micrococcus luteus reductionThis study was conducted by the Academic Health Science Networks (AHSN) as part of the National Health Services Environmental decontamination framework evaluation in the UK.
The Defend 400 device was evaluated against Micrococcus luteus bacteria over 1 hour in a room setting to determine the disinfection capabilities against aerosolised bacteria.
Micrococcus luteus reductionConducted by the Academic Health Science Networks (AHSN), this study is part of the National Health Services Environmental decontamination framework evaluation in the UK.
The effectiveness of the Defend 1050 device was evaluated against Micrococcus luteus bacteria. Tests mimicked real-world settings to determine the disinfection capabilities against aerosolised bacteria in a room.
MS2 bacteriophageNovaerus Defend 1050 was shown to reduce MS2 bacteriophage virus, a surrogate for SARS-CoV-2, RSV, Influenza A, and Norovirus, by 99.99% in 15 minutes at Aerosol Research and Engineering Laboratories.
Mycobacterium tuberculosis Bacteria ReductionNovaerus Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by 97% after 30 minutes of operation at the Airmid Healthgroup.
Mycobacterium tuberculosis InactivationThe Novaerus Protect 200 (NV200/330) rendered all airborne Mycobacterium tuberculosis non-viable at Qualilife Diagnostics in India.
Nitrogen Dioxide ReductionNovaerus Defend 1050 reduced the chamber concentration of Nitrogen Dioxide (NO2) to 0.0 ppm at 7.5 minutes in all three trials at Aerosol Research and Engineering Laboratories.
Particle ReductionNovaerus Defend 1050 removed 99% of PM2.5 within 6.26 minutes and 99% of PM1.0 within 6.33 minutes at Camfil Laboratories – Tech Center in Sweden.
Particle ReductionThe Defend 400 reduced PM 1 by 99.99% in 26 minutes with an eCADR of 340.7 m3/h. PM 2.5 was reduced by 99.99% in 25.9 minutes with an eCADR of 341.0 m3/h.
Phi X 174 Virus ReductionNovaerus Defend 1050 was shown to reduce phi X 174 virus, a surrogate for Hepatitis B23, Hepatitis C23 and HIV2 by 98.8% in 30 minutes at the Korea Testing Laboratory.
Staphylococcus epidermidis Bacteria ReductionThe Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.
Staphylococcus epidermidis Bacteria ReductionNovaerus Defend 1050 was shown to reduce Staphylococcus epidermidis bacteria by 99.9% in 60 minutes at the Korea Testing Laboratory.
Staphylococcus epidermidis Bacteria ReductionNovaerus Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis within 15 minutes of operation at the Novaerus Research and Development Labs.
Staphylococcus epidermidis Bacteria ReductionNovaerus shown to reduce 95% of Staphylococcus epidermidis aerosol contamination in 30 minutes at the University of Huddersfield in England.
VOC ReductionNovaerus Defend 1050 achieved 90% VOC removal after 6 - 16 minutes, dependent on fan speed at Camfil Laboratories – Tech Center in Sweden.
Reduction of Enterobacter, Salmonella, and ListeriaThe Defend 1050 was shown to reduce 99.99% of aerolized Enterobacter cloacae, Salmonella enterica and Listeria innocua in 15 minutes and exceeded a 6 net log reduction in 20 minutes.
- Evaluation of the Protect 800/900 in a Hospital Laboratory
WellAir’s Novaerus Protect 800/900 air cleaning device was used in the University Hospitals Birmingham's Hospital Infection Research Laboratory — results showed a statisctially significant reduction in total viable counts of microbial bioburden.
Evaluation of the Defend 400 in a Hospital Operating RoomA Hospital in Glen Echo, MD evaluates WellAir’s Novaerus Defend 400 air cleaning device in an operating room — results showed a substantial reduction in airborne bacterial bioburden over an 2-day period.
Evaluation of the Defend 1050 in Hospital Staff BreakroomThe use of the FDA-Cleared Defend 1050 portable stand-alone air cleaner in a hospital breakroom at Northwell Health in New York (North Shore University Hospital) showed a substantial reduction in airborne bacterial bioburden overall.
Evaluation of the Defend 400 in an Urgent Care Outpatient FacilityDuring the 5 consecutive days at Cape Regional Urgent Care in New Jersey, the Defend 400 significantly reduced total bacterial count by 52%, which included a 60% reduction in opportunistic pathogens and a 43% reduction in pathogenic bacteria.
Evaluation of the Protect 800/900 and Defend 1050 in a Hospital ICUWellAir’s Novaerus devices help to reduce the microbial load in the air and surfaces and thus hospital-acquired infections. This intervention study was conducted in two similar ICUs in Turkey between May to November of 2020.
Evaluation of the Novaerus Technology in a Dialysis CentreNovaerus reduces VOCs by 93%, airborne bacteria by 87% and moulds by 67% at two Fresenius Dialysis Centres in Portugal.
Evaluation of the Protect 200 and Protect 800 in an Emergency HospitalNovaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87% at the Bucharest Emergency University Hospital in Romania.
Evaluation of the Protect 200 in Hospital Wards: Leopardstown Park HospitalNovaerus reduces staff sickness, ward odours, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation at the Leopardstown Park Hospital in Dublin.
Evaluation of the Protect 800/900 in a HospitalNovaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA at the Royal Free Hospital in London.
Evaluation of the Protect 200 and Protect 800/900 in an Infectious Disease HospitalNovaerus shown to reduce airborne bacteria and fungi 96% at the “Dr V. Babes” Hospital of Infectious and Tropical Diseases in Bucharest, Romania.
Evaluation of the Novaerus Technology in Intensive CareNovaerus plasma technology shown to significantly reduce number of microorganisms at Brothers Hospitallers of Saint John of God Hospital in Łódź, Poland.
Evaluation of the Novaerus Technology in a Nephrology ClinicNovaerus shown to reduce bacterial loads on high surfaces and window sills as well as reduce overall infection rates by 23% compared to increase of infection rates by 35% in control section at Rigshospitalet in Copenhagen, Denmark.
Evaluation of the Protect 800/900 in an Ophthalmology Operating RoomNovaerus reduces bacterial colony count in both the rooms that were being used and those that were empty at Ain Shams University in Cairo, Egypt.
Evaluation of the Novaerus Technology in a Paediatric DepartmentNovaerus devices effectively reduce the number of airborne pathogens by 61% in the admission room of the Paediatric Department and by 19% in the Clinic of Pulmonology/Tuberculosis and Pulmonary Diseases at Międzyrzecz Hospital in Międzyrzecz, Poland.
Evaluation of the Protect 200 and Protect 800/900 in a Pulmonology DepartmentNovaerus reduces CFU rates by 82% and fungi count by 93% after 2 months of operation at the Uzsoki Hospital in Budapest, Hungary.
Evaluation of the Protect 200 and Protect 800/900 in a Specialised HospitalNovaerus devices significantly reduce number of microorganisms as well as eliminate unwanted odours at Specialised Hospital in Chorzów, Poland.
Evaluation of the Protect 200 in Inactivation of Airborne Acinetobacter speciesThe evaluation measured the efficacy of the Protect 200 in rendering airborne five clinical isolates of Acinetobacter species. It was observed that positive control blood agar and MacConkey’s agar plates showed growth, whereas inoculated plates showed no growth in 48 hours.
- Beijing Red Cross Blood Center Case Study
In the midst of the pandemic, life's pace slowed significantly, impacting various sectors. However, the operations of the world's blood banks, including the Beijing Red Cross Blood Center, remained crucial. To ensure the uninterrupted functioning of blood banks, Novaerus air disinfection devices, powered by the patented NanoStrike™ air disinfection technology, were deployed.
Leopardstown Park Hospital Case StudyIn an effort to reduce odour, Leopardstown Park Hospital installed a number of Protect 200s and Protect 800s throughout a ward. After one year, the ward using the Novaerus devices observed a 46% reduction in staff sickness. Leopardstown Park also observed no outbreaks of MRSA, C. diff, Influenza, or Norovirus.
Broward Children's Case StudyThis 20-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology.
Canterbury Tower Case StudyThis 35-month study compares the total number of respiratory nosocomial infections and infection rates before and after each implementation of the Novaerus technology.
Dance Again Case StudyBelgium was one of the worst-hit countries in Europe by the COVID-19 pandemic, with 2,100 deaths per million people. However, the tide began to turn in 2021 as the Belgian government implemented a successful vaccination programme, with almost 13.5 million doses administered to date. The swift vaccine rollout, along with the marked reduction in infection rates, increasingly led to calls for the reopening of hospitality venues, including the nightlife sector.
Edgehill Case StudyThis 24-month study compares the total number of respiratory nosocomial infections before and after implementation of the Novaerus technology at Edgehill Nursing and Rehabilitation Center (ENRC) in Pennsylvania.
Haus an der Traisen Case StudySince 2014, the Haus an der Traisen nursing home in St. Pölten (Austria) have supplemented their existing hygiene protocols with Novaerus air purification units to help control infection and reduce odour.
Hialeah Case StudyThis 24-month study compares the total number of repeat infections, nosocomial C. difficile infections, and nosocomial respiratory infections before and after implementation of the Novaerus technology at Hialeah Nursing and Rehab Center (HNRC) in Florida.
Linde Healthcare Case StudyLinde Healthcare, a Vienna-based healthcare company, had no existing healthy air solution in place for its 16 person open floorplan office space. Curious about Novaerus’s innovative technology, they reached out to learn more.
Manchester Manor Case StudyThis 24-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Manchester Manor Health Care Center (MMHCC) in Connecticut.
Masfiv Medical Centre Case StudyAs COVID-19 rapidly spread across the globe, healthcare facilities around the world had to adapt. For Masfiv, a newly built medical centre specializing in reproductive medicine and gynaecological health, this meant maintaining minimal essential reproductive care services while containing the spread of coronavirus. Masfiv established a range of COVID-19 protocols including 24/7 air disinfection technology by Novaerus.
Meadow View Case StudyThis 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Meadow View Nursing Center (MVNC) in Pennsylvania.
Naamans Creek Case StudyThis 28-month study compares the total number of nosocomial respiratory infections and nosocomial C. difficile infections before and after implementation of the Novaerus technology at Naamans Creek Country Manor (NCCM) in Pennsylvania.
Page Case StudyThis 29-month study compares the average monthly rate of nosocomial respiratory infections before and after implementation of the Novaerus technology at Page Rehabilitation and Healthcare Center (PRHC) in Florida.
Patki Hospital and IVF Centre Case StudyPatki Hospital, an IVF centre specialized in obstetrics, infertility and gynaecology in India, were looking for a solution to reduce airborne VOC and infection load in their lab. After investigating various options, the hospital decided to deploy a Novaerus Defend 1050. The result; improved outcomes and air quality.
Sante International Case StudySante International has provided solutions to the Romanian healthcare industry since 1992 and has partnered with Novaerus since 2014. Over a 3-month period, they proved Novaerus technology is more efficient and safer with no maintenance and at a low cost.
University of Szeged Case StudyAs part of a trial to measure background pollution and pathogenic organisms, Novaerus units were placed in 4 locations in the University of Szeged’s Department of Geriatrics and Chronic Diseases of the Internal Medicine Clinic No. 1. The medical clinic was interested in improving overall air quality in the geriatric and chronic disease wards.
Vernon Manor Case StudyThis 24-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology at Vernon Manor Health Care Center (VMHCC) in Connecticut.
Village at Manor Park Case StudyThis 23-month study compares the total number of nosocomial respiratory infections before and after implementation of the Novaerus technology.
Wassan Dental Speciality Centre Case StudyTwo weeks after installation, Wassan Dental (Oman) staff observed a noticeable reduction in odour. Staff were reassured to know that Novaerus was operating continuously in the background to eliminate VOC, infectious pathogens and allergens from the air.
Uzsoki Hospital Case StudyIn Hungary, the COVID-19 health crisis prompted the establishment of mandatory specialized facilities for all in-patient healthcare institutions. For Uzsoki Hospital, a busy, high-traffic hospital in Budapest, this meant transforming its Department of Pulmonology to a ward specially designed to deal with the virus.
TradFest Temple Bar Case StudyAs Covid-19 spread around the world, live music events everywhere were cancelled or postponed. TradFest Temple Bar, an annual live music festival celebrating Irish music and culture, reimagined their iconic event with the help of Novaerus air disinfection technology from WellAir.
